[충청뉴스 이성현 기자] A research team in Korea has developed treatment candidates for rheumatoid arthritis and lymphatic cancer, which are rare incurable diseases.
The Korea Research Institute of Chemical Technology (KRICT) conducted research on developing a treatment for ‘autoimmune disease’, where inflammation is caused and normal tissues are attacked by a defect in the immune system, by Dr Heeyoung Cho and Dr. Heejong Lim’s research team announced on the 7th that it has developed a new substance to treat rheumatoid arthritis and lymphatic cancer by preventing
Rheumatoid arthritis is the most common autoimmune disease affecting almost 1% of the world’s population Drugs such as anti-inflammatory drugs and biologic anti-rheumatic injections are prescribed, but most patients show resistance to long-term drug treatment, reduction in drug effectiveness, and improving immunity They still suffer from side effects such as deterioration.
In particular, excessive inflammation is a representative carcinogen, and in particular, ‘ABC-DLBCL type lymphoma’, which is the type with the worst prognosis among blood cancers, is known to be an important treatment strategy to alleviate inflammation by inhibiting the IRAK4 enzyme.
In the case of ‘Tofacitinib’, a drug first developed and widely used as an oral rheumatoid arthritis treatment, the risk of serious cardiovascular side effects such as heart attack has recently been established, and ‘Ibrutinib’, which lymphatic cancer treatment, after a long term It is explained that combination therapy with other drugs is necessary due to the development of resistance when taking it.
Accordingly, the research team conducted a study to find a substance that could selectively block the body’s excessive inflammatory response. By blocking it, a candidate was developed for ‘KIC-0101’, a treatment drug that improves rheumatoid arthritis and lymphatic cancer.
The developed drug significantly improved arthritis symptoms when administered to animal models of rheumatoid arthritis, and when administered in combination with the existing treatment, ‘ibrutinib’ to drug-resistant lymphatic cancer cells, it was observed that the transmission of inflammatory signals blocked and the size. The lymphoma was significantly reduced.
As a result of short-term oral administration of the developed drug (KIC-0101) to a rheumatoid arthritis antibody-inducing animal model (CAIA) for 10 days or long-term oral administration to an animal model that stimulating collagen (CIA) for 10 weeks, arthritis values such as edema and ankle thickness were improved. It was found that the treatment effect was reduced by 68-80% and the inflammatory area was improved to a normal level.
In addition, when ‘KIC-0101’ was administered alone or in combination for 14 days to an animal tumor model in which lymphatic cancer cells were injected subcutaneously, it was confirmed that cancer tissue growth was inhibited by more than 80 %.
The Director of the Chemical Technology Research Institute said, “This achievement is another new material obtained through the research into new drugs that the Research Institute has been continuously striving towards, and we expect it to be developed as a global new drug. which can improve the quality of life of patients with incurable diseases.” revealed
Meanwhile, non-clinical trials are being carried out for the treatment of rheumatoid arthritis and lymphatic cancer developed by the research team in collaboration with Future Medicine.
Copyright © Chungcheong News Unauthorized reproduction and redistribution prohibited
